Edenbridge Pharmaceuticals Names Douglas S. Boothe as CEO
Edenbridge Pharmaceuticals, the U.S. subsidiary of Dexcel Pharma, today announced that Douglas S. Boothe has been named Chief Executive Officer, effective January 1, 2024. Boothe is an industry veteran with extensive accomplishments in the specialty, generic and over-the-counter pharmaceuticals business.
Boothe has expertise in general management, strategy, sales and marketing, product selection, supply chain and business development in both the U.S. and global arenas. Over the course of his career, Boothe has overseen many successful new product development projects, regulatory reviews and approvals, paragraph IV litigations and commercial launches. He has also reinvigorated research and development, regulatory, compliance and supply chain platforms in his past roles.
"I am delighted to welcome Doug to Edenbridge at this pivotal time for the company," said Ilan Oren, Co-Chief Executive Officer of Dexcel Pharma. "Doug's deep pharmaceuticals expertise and proven track record aligns well with our growth strategy, and will help drive our vision of creating a broad portfolio of limited source pharmaceutical products and providing high-quality, affordable and accessible alternatives in a large and very important healthcare market."
Boothe said, "I am excited about the opportunity to lead Edenbridge Pharmaceuticals and to expand our U.S. footprint through product acquisition and development partnerships with a focus on quality, affordability and accessibility."
Booth will succeed Edenbridge President and Co-founder Patrick Chu, who will retire from the Company.
Oren added, "On behalf of the entire Dexcel organization, I'd like to thank Patrick for his tremendous leadership and contributions in building Edenbridge and positioning the organization for success."
About Douglas S. Boothe
Most recently, Boothe served as the President and Chief Executive Officer of Akorn, Inc. Prior to that, he was President of the generics division of Impax Laboratories, which developed, manufactured and marketed bioequivalent pharmaceuticals and was acquired by Amneal Pharmaceuticals LLC in a reverse merger transaction in May 2018. Earlier roles include Executive Vice President and General Manager of Perrigo Company Plc, with responsibility for the approximately $1 billion U.S. pharmaceuticals business, which included generics and specialty pharmaceutical products. He also served as the CEO of Actavis Inc., the U.S. manufacturing and marketing division of Actavis Group, and held senior positions at Alpharma and Pharmacia Corp. Boothe received his undergraduate degree from Princeton University and his MBA from the Wharton School of Business at the University of Pennsylvania.
About Edenbridge
Edenbridge Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and marketing prescription pharmaceutical products. Our goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable and accessible alternatives in the healthcare market. Our approach is to work with best-in-class and like-minded industry partners to deliver our products to physicians and patients everywhere.
Founded in 2008, we launched our first product in February 2010 and have sold our commercial products through every major channel of the U.S. prescription pharmaceutical supply chain. In addition, we have a robust product development pipeline that includes 505(b)(2) NDAs, ANDAs, and foreign filings.
News published on and distributed by:
